ArticleScientific reports2026
ScaleMamba-YOLO: a multi-scale MambaYOLO for medical object detection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The efficacy of automated lesion detection in clinical settings is often hampered by two primary factors: the vast range of pathological scales and the presence of non-target anatomical interference. Standard Mamba-based detectors, while efficient, frequently suffer from fixed receptive fields and background signal leakage. To resolve these challenges, we introduce ScaleMamba-YOLO, an enhanced medical object detection framework that integrates selective state-space modeling with adaptive local feature refinement. Our approach features two innovative structural components: first, a Medical Multi-scale Local Feature Enhancement Block (MMLFE-Block) is positioned at the frontend to diversify the initial receptive field. By utilizing a parallel architecture with heterogeneous convolutional kernels (1×1, 3×3, and 5×5), the model achieves comprehensive hierarchical perception, enabling the concurrent identification of minute calcified spots and extensive diffuse lesions. Second, a Partial-Enhanced C2F (PEC2F) module is designed to refine feature aggregation post-global modeling. This component employs partial convolution (PConv) to selectively process salient feature channels, effectively filtering out irrelevant background noise from normal tissue structures. The robust performance of ScaleMamba-YOLO was validated across three specialized medical datasets (Br35H, BCCD, and PLoPy) and a standard scene dataset (VOC0712). The model recorded Average Precision (AP) scores of 72.7%, 65.0%, 85.7%, and 64.6%, respectively. These metrics represent consistent improvements of 1.7% to 2.3% over the MambaYOLO baseline, underscoring the system's potential for high-fidelity diagnostic assistance in real-time clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.